Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 12

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

TP53 and therapy-related myeloid neoplasms

Chung, Jae, Sallman, David A., Padron, Eric·2019·Best Practice & Research Clinical Haematology
DOI 10.1016/j.beha.2019.02.009
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.beha.2019.02.009

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 40

  1. Godley, 2008, Therapy-related myeloid leukemia, Semin Oncol, 35, 418, 10.1053/j.seminoncol.2008.04.012 · DOI · Paper page
  2. Singh, 2007, Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant, Am J Clin Pathol, 127, 197, 10.1309/NQ3PMV4U8YV39JWJ · DOI
  3. Smith, 2003, Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series, Blood, 102, 43, 10.1182/blood-2002-11-3343 · DOI · Paper page
  4. Christiansen, 2001, Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis, J Clin Oncol, 19, 1405, 10.1200/JCO.2001.19.5.1405 · DOI · Paper page
  5. Ok, 2015, TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases, J Hematol Oncol, 8, 45, 10.1186/s13045-015-0139-z · DOI
  6. Levine, 1997, p53, the cellular gatekeeper for growth and division, Cell, 88, 323, 10.1016/S0092-8674(00)81871-1 · DOI · Paper page
  7. Harris, 1993, Clinical implications of the p53 tumor-suppressor gene, N Engl J Med, 329, 1318, 10.1056/NEJM199310283291807 · DOI · Paper page
  8. Cancer Genome Atlas Research, 2013, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia, N Engl J Med, 368, 2059, 10.1056/NEJMoa1301689 · DOI · Paper page
  9. Prokocimer, 2017, Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy, Blood, 130, 699, 10.1182/blood-2017-02-763086 · DOI · Paper page
  10. Chang, 1995, Implications of the p53 tumor-suppressor gene in clinical oncology, J Clin Oncol, 13, 1009, 10.1200/JCO.1995.13.4.1009 · DOI · Paper page
  11. Kubbutat, 1997, Regulation of p53 stability by Mdm2, Nature, 387, 299, 10.1038/387299a0 · DOI · Paper page
  12. Haupt, 1997, Mdm2 promotes the rapid degradation of p53, Nature, 387, 296, 10.1038/387296a0 · DOI · Paper page
  13. Barak, 1993, mdm2 expression is induced by wild type p53 activity, EMBO J, 12, 461, 10.1002/j.1460-2075.1993.tb05678.x · DOI · Paper page
  14. Lane, 1992, Cancer. p53, guardian of the genome, Nature, 358, 15, 10.1038/358015a0 · DOI · Paper page
  15. Bowen, 2009, TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis, Leukemia, 23, 203, 10.1038/leu.2008.173 · DOI · Paper page
  16. Kadia, 2016, TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes, Cancer, 122, 3484, 10.1002/cncr.30203 · DOI · Paper page
  17. Grossmann, 2012, A novel hierarchical prognostic model of AML solely based on molecular mutations, Blood, 120, 2963, 10.1182/blood-2012-03-419622 · DOI · Paper page
  18. Rucker, 2012, TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome, Blood, 119, 2114, 10.1182/blood-2011-08-375758 · DOI · Paper page
  19. Sallman, 2016, Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes, Leukemia, 30, 666, 10.1038/leu.2015.304 · DOI · Paper page
  20. Goel, 2016, High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort, Leukemia, 30, 1793, 10.1038/leu.2016.74 · DOI
  21. Weisz, 2007, Transcription regulation by mutant p53, Oncogene, 26, 2202, 10.1038/sj.onc.1210294 · DOI · Paper page
  22. Dittmer, 1993, Gain of function mutations in p53, Nat Genet, 4, 42, 10.1038/ng0593-42 · DOI · Paper page
  23. Wolf, 1984, Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene, Cell, 38, 119, 10.1016/0092-8674(84)90532-4 · DOI · Paper page
  24. Deyoung, 2007, p63 and p73 in human cancer: defining the network, Oncogene, 26, 5169, 10.1038/sj.onc.1210337 · DOI · Paper page
  25. Laurie, 2012, Detectable clonal mosaicism from birth to old age and its relationship to cancer, Nat Genet, 44, 642, 10.1038/ng.2271 · DOI · Paper page
  26. Genovese, 2015, Clonal hematopoiesis and blood-cancer risk, N Engl J Med, 372, 1071, 10.1056/NEJMc1500684 · DOI
  27. Xie, 2014, Age-related mutations associated with clonal hematopoietic expansion and malignancies, Nat Med, 20, 1472, 10.1038/nm.3733 · DOI · Paper page
  28. Jaiswal, 2014, Age-related clonal hematopoiesis associated with adverse outcomes, N Engl J Med, 371, 2488, 10.1056/NEJMoa1408617 · DOI · Paper page
  29. Wong, 2016, Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML, Blood, 127, 893, 10.1182/blood-2015-10-677021 · DOI
  30. Gibson, 2017, Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma, J Clin Oncol, 35, 1598, 10.1200/JCO.2016.71.6712 · DOI · Paper page
  31. Ellis, 2008, MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility, Blood, 112, 741, 10.1182/blood-2007-11-126508 · DOI
  32. Desai, 2018, Somatic mutations precede acute myeloid leukemia years before diagnosis, Nat Med, 24, 1015, 10.1038/s41591-018-0081-z · DOI · Paper page
  33. Devillier, 2015, Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes, Oncotarget, 6, 8388, 10.18632/oncotarget.3460 · DOI
  34. Haferlach, 2008, Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype, Leukemia, 22, 1539, 10.1038/leu.2008.143 · DOI · Paper page
  35. Fang, 2011, Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation, Blood, 118, 1490, 10.1182/blood-2011-02-339721 · DOI
  36. Middeke, 2014, Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation, Blood, 123, 2960, 10.1182/blood-2013-12-544957 · DOI
  37. Dohner, 2018, Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care, Leukemia, 32, 2546, 10.1038/s41375-018-0257-z · DOI
  38. Welch, 2016, TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes, N Engl J Med, 375, 2023, 10.1056/NEJMoa1605949 · DOI · Paper page
  39. Montalban-Bravo, 2017, Decitabine in TP53-mutated AML, N Engl J Med, 376, 796, 10.1056/NEJMc1616062 · DOI
  40. Wang, 2017, Targeting the MDM2-p53 protein-protein interaction for new cancer therapy: progress and challenges, Cold Spring Harb Perspect Med, 7, 10.1101/cshperspect.a026245 · DOI · Paper page

Cited by

See all 12

Metadata

Authors
Chung, J., Sallman, D. A., & Padron, E.
Venue
Best Practice & Research Clinical Haematology
Publisher
Elsevier BV
Published
2019-03
Volume
32
Issue
1
Pages
98-103
ISSN
1521-6926
DOI
10.1016/j.beha.2019.02.009
Cited by
12
References
9
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TP53 and therapy-related myeloid neoplasms. https://app.cochat.ai/papers/10.1016/j.beha.2019.02.009
The paper
Chung, J., Sallman, D. A., & Padron, E. (2019). TP53 and therapy-related myeloid neoplasms. Best Practice & Research Clinical Haematology. https://doi.org/10.1016/j.beha.2019.02.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.